ID   WM852
AC   CVCL_6804
SY   WM-852; WM 852; WML 852; WC00065; EST84
DR   cancercelllines; CVCL_6804
DR   Coriell; WC00065
DR   Cosmic; 886832
DR   Cosmic; 972282
DR   Cosmic; 1047657
DR   Cosmic; 1155275
DR   Cosmic; 1303079
DR   Cosmic; 2163811
DR   Cosmic; 2479249
DR   ESTDAB; ESTDAB-084
DR   GEO; GSM109044
DR   GEO; GSM156017
DR   GEO; GSM952601
DR   IARC_TP53; 1193
DR   IARC_TP53; 26084
DR   Progenetix; CVCL_6804
DR   Rockland; WM852-01-0001
DR   Wikidata; Q54994323
RX   PubMed=4053039;
RX   PubMed=8342600;
RX   PubMed=15592718;
RX   PubMed=16827748;
RX   PubMed=17260012;
RX   PubMed=19340423;
RX   PubMed=23851445;
WW   https://www.wistar.org/our-scientists/meenhard-herlyn
CC   Part of: Wistar Institute melanoma cell line collection.
CC   HLA typing: A*03:01,02:01; B*15:01:01:01,07:02; C*03:04,07:02; DPB1*04:01; DQB1*06:02,03:02; DRB1*04:01,15:01 (PubMed=15592718).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=17260012).
CC   Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Hemizygous (Wistar).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; None_reported; -; Zygosity=- (Wistar).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=17260012; PubMed=23851445; Wistar).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser241Phe (c.722C>T); ClinVar=VCV000012359; Zygosity=Unspecified (PubMed=17260012; PubMed=23851445).
CC   Omics: Array-based CGH.
CC   Omics: Transcriptome analysis by microarray.
CC   Caution: The reported STR profile from Wistar of this cell line was changed at one point between February 2016 when we retrieved them and entered them in the Cellosaurus and May 2018. The major changes were: D18S51: 18->16, D5S818: 12,13->13, D8S1179: 12,13->13 and FGA: 21->21,26.
CC   Misspelling: VM852; Cosmic=2479249.
CC   Discontinued: Coriell; WC00065; probable.
CC   Derived from site: Metastatic; Abdomen, skin; UBERON=UBERON_0001416.
ST   Source(s): ESTDAB=ESTDAB-084; Wistar
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 11,12
ST   D16S539: 13,14
ST   D18S51: 16
ST   D19S433: 13,14
ST   D21S11: 30
ST   D2S1338: 16,17
ST   D3S1358: 15,18
ST   D5S818: 13
ST   D7S820: 8,10
ST   D8S1179: 13
ST   FGA: 21,26
ST   TH01: 6,7
ST   TPOX: 8
ST   vWA: 14,15 (Wistar)
ST   vWA: 15,17 (ESTDAB=ESTDAB-084)
DI   NCIt; C3510; Cutaneous melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   63Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 32
//
RX   PubMed=4053039;
RA   Herlyn M., Thurin J., Balaban G.B., Bennicelli J.L., Herlyn D.,
RA   Elder D.E., Bondi E., Guerry D. IV, Nowell P.C., Clark W.H. Jr.,
RA   Koprowski H.;
RT   "Characteristics of cultured human melanocytes isolated from different
RT   stages of tumor progression.";
RL   Cancer Res. 45:5670-5676(1985).
//
RX   PubMed=8342600;
RA   Juhasz I., Albelda S.M., Elder D.E., Murphy G.F., Adachi K.,
RA   Herlyn D., Valyi-Nagy I.T., Herlyn M.;
RT   "Growth and invasion of human melanomas in human skin grafted to
RT   immunodeficient mice.";
RL   Am. J. Pathol. 143:528-537(1993).
//
RX   PubMed=15592718; DOI=10.1007/s00262-004-0561-5;
RA   Rodriguez T., Mendez R., Roberts C.H., Ruiz-Cabello Osuna F., Dodi I.A.,
RA   Lopez-Nevot M.A., Paco L., Maleno I., Marsh S.G.E., Pawelec G.,
RA   Garrido F.;
RT   "High frequency of homozygosity of the HLA region in melanoma cell
RT   lines reveals a pattern compatible with extensive loss of
RT   heterozygosity.";
RL   Cancer Immunol. Immunother. 54:141-148(2005).
//
RX   PubMed=16827748; DOI=10.1111/j.1600-0749.2006.00322.x;
RA   Hoek K.S., Schlegel N.C., Brafford P., Sucker A., Ugurel S., Kumar R.,
RA   Weber B.L., Nathanson K.L., Phillips D.J., Herlyn M., Schadendorf D.,
RA   Dummer R.;
RT   "Metastatic potential of melanomas defined by specific gene expression
RT   profiles with no BRAF signature.";
RL   Pigment Cell Res. 19:290-302(2006).
//
RX   PubMed=17260012; DOI=10.1038/sj.onc.1210252;
RA   Jonsson G., Dahl C., Staaf J., Sandberg T., Bendahl P.-O., Ringner M.,
RA   Guldberg P., Borg A.;
RT   "Genomic profiling of malignant melanoma using tiling-resolution
RT   arrayCGH.";
RL   Oncogene 26:4738-4748(2007).
//
RX   PubMed=19340423; DOI=10.1007/s00262-009-0701-z;
RA   Mendez R., Aptsiauri N., Del Campo A., Maleno I., Cabrera T.,
RA   Ruiz-Cabello Osuna F., Garrido F., Garcia-Lora A.;
RT   "HLA and melanoma: multiple alterations in HLA class I and II
RT   expression in human melanoma cell lines from ESTDAB cell bank.";
RL   Cancer Immunol. Immunother. 58:1507-1515(2009).
//
RX   PubMed=23851445; DOI=10.1158/1541-7786.MCR-13-0006;
RA   Dahl C., Christensen C., Jonsson G., Lorentzen A., Skjodt M.L.,
RA   Borg A., Pawelec G., Guldberg P.;
RT   "Mutual exclusivity analysis of genetic and epigenetic drivers in
RT   melanoma identifies a link between p14 ARF and RARbeta signaling.";
RL   Mol. Cancer Res. 11:1166-1178(2013).
//